保寶龍科技(01861.HK)附屬訂立廠房建築協議
格隆匯 4 月 12日丨保寶龍科技(01861.HK)公吿,於2021年4月12日,公司全資附屬公司Precious Dragon Thai與State Construction及S.P.64分別就在該土地設計及建設該廠房訂立建築協議,總合約金額(包括增值税及其他適用税項)分別為約3080萬港元及約2240萬港元。
根據建築協議,承建商將(其中包括)執行該廠房的結構及建築工程,包括生產線、倉庫及辦公室。
集團主要從事氣霧罐內容填充,以及氣霧劑產品及非氣霧劑產品的生產及銷售。集團的產品包括汽車美容及保養產品、個人護理產品及其他產品。集團主要於中國內地、日、中東、美國及亞洲經營業務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.